The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
ASH 2018 | Practice changing abstracts in graft-versus-host disease
Did you miss ASH 2018? The GvHD Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA, USA, and has developed a downloadable resource, which provides information on the practice changing abstracts across graft-versus-host disease (GvHD).
Our selection of ASH abstracts include comments from The GvHD Hub Steering Committee members on promising new therapeutic and prophylactic options; ruxolitinib for steroid refractory GvHD, KD025 for chronic GvHD, and vedolizumab for GvHD prophylaxis. Hear from the experts on the role of the microbiome, genetic risk factors and potential biomarkers in GvHD.
ASH 2018 | Practice changing abstracts in graft-versus-host disease
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the GvHD Hub resource below:
#601: Results from REACH1, a single-arm phase II study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease
http://www.gvhdhub.com/medical-information/ash-2018-ruxolitinib-plus-corticosteroids-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-the-reach1-trial
#602: KD025-208: A phase IIa study of KD025 for patients with chronic graft versus host disease (cGVHD) - pharmacodynamics and updated results
http://www.gvhdhub.com/medical-information/ash-2018-pharmacodynamics-and-updated-data-from-the-phase-iia-kd025-208-trial
#605: A phase Ib study of intravenous vedolizumab plus standard of care for graft-versus-host disease prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies: 6-month results
http://www.gvhdhub.com/medical-information/ash-2018-vedolizumab-plus-standard-of-care-to-prevent-graft-versus-host-disease-a-phase-ib-study
#603: Children and adults with steroid-refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation "MSC-Ffm": treatment results for 92 consecutive patients
http://www.gvhdhub.com/medical-information/ash-2018-msc-ffm-for-the-treatment-of-pediatric-and-adult-patients-with-steroid-refractory-graft-versus-host-disease
#69: Metabolomics profiling after allogeneic hematopoietic stem cell transplantation unravels a specific signature in human acute GvHD
http://www.gvhdhub.com/medical-information/ash-2018-the-role-of-metabolomics-profiling-in-acute-graft-versus-host-disease
#359: Pre-transplant and peri-d100 gastrointestinal dysbiosis is associated with the subsequent development of chronic graft-versus-host disease
http://www.gvhdhub.com/medical-information/kate-a-markey-ash-2018-pre-transplant-and-peri-d100-gastrointestinal-dysbiosis-in-chronic-gvhd
#357: Genetic risk of severe chronic graft-versus-host disease defined by host-derived CXCR3 ligands
https://gvhdhub.com/medical-information/prediction-of-severe-chronic-graft-versus-host-disease-by-host-derived-cxcr3-ligand-genes
#356: Serial biomarker monitoring early after HCT identifies different risks for relapse and graft-vs-host disease
https://gvhdhub.com/medical-information/james-ferrara-ash-2018-how-biology-drives-acute-gvhd-biomarkers